Pharmaterials-B (02617.HK): Application for Approval of New Drug Tenofovir Disoproxil Fumarate Tablets Accepted by the National Medical Products Administration.

Wisdom Finance APP news, Pharmaron-B (02617.HK) announced that the new drug application for Tegrealtenib tablets has been accepted by the China National Medical Products Administration Drug Evaluation Center. It is intended for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received at least one systemic therapy and FGFR inhibitor therapy. Previously, the indication for Tegrealtenib tablets has been approved for priority review and breakthrough therapy designation.